Drug name - Olumiant
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8158616 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Jun, 2030
(7 years from now) | |
| CN103788098A | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitor |
May, 2016
(6 years ago) | |
| CN102026999B | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitor |
Mar, 2029
(6 years from now) | |
| CN102026999A | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| IN201001863P3 | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| IN270765B | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| EP2288610B1 | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| EP2288610A1 | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| EP2288610B8 | ELI LILLY AND CO | Azetidine And Cyclobutane Derivatives As Jak Inhibitors |
Mar, 2029
(6 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8420629 | ELI LILLY AND CO | Azetidine and cyclobutane derivatives as JAK inhibitors |
Mar, 2029
(6 years from now) | |
Drugs and Companies using BARICITINIB ingredient
Treatment: Treatment of rheumatoid arthritis
Dosage: TABLET;ORAL
More Information on Dosage
| Strength | Dosage | Availability |
|---|---|---|
| 1MG | TABLET;ORAL | Prescription |
| 2MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.